Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

Yi Li, Quanmin Jing, Bing Wang, Xiaozeng Wang, Jing Li, Shubing Qiao, Shaoliang Chen, Dominick J Angiolillo, Yaling Han, Yi Li, Quanmin Jing, Bing Wang, Xiaozeng Wang, Jing Li, Shubing Qiao, Shaoliang Chen, Dominick J Angiolillo, Yaling Han

Abstract

Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention. However, the optimal antiplatelet strategy for ACS patients with both high bleeding and high ischemic risks is unclear.

Study design: The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk"). A total of 7,700 patients who completed 9- to 12-month dual antiplatelet therapy after new-generation drug-eluting stent implantation for the treatment of ACS will be randomized to receive clopidogrel monotherapy or aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months. The primary end point is Bleeding Academic Research Consortium type 2, 3, or 5 bleedings at 9 months after randomization. The key secondary end point is major adverse cardiac and cerebral events at 9 months after randomization, defined as a composite of all-cause death, myocardial infarction, stroke, or coronary artery revascularization.

Conclusions: OPT-BIRISK is the first large-scale randomized trial aimed to explore the optimal antiplatelet strategy for bi-risk ACS patients after percutaneous coronary intervention in current clinical practice. The results will add evidence regarding de-escalation antiplatelet therapy for patients at special risk.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39(3):213–260.
    1. Levine G.N., Bates E.R., Bittl J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–1115.
    1. Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915–2931.
    1. Yeh R.W., Secemsky E.A., Kereiakes D.J., et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–1749.
    1. Costa F., van Klaveren D., James S., et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–1034.
    1. Baber U., Mehran R., Giustino G., et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–2234.
    1. Han Y., Chen J., Qiu M., et al. Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: the OPT-CAD risk score. Cardiovasc Ther. 2018;36(5)
    1. Capodanno D., Angiolillo D.J. Tailoring duration of DAPT with risk scores. Lancet. 2017;389(10073):987–989.
    1. Tantry U.S., Bonello L., Aradi D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013 Dec 17;62(24):2261–2273.
    1. Mauri L., Kereiakes D.J., Yeh R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166.
    1. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800.
    1. Verdoia M., Kedhi E., Ceccon C., et al. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials. Int J Cardiol. 2018;264:30–38.
    1. Capodanno D., Mehran R., Valgimigli M., et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018;15(8):480–496.
    1. Vranckx P., Valgimigli M., Jüni P., et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–949.
    1. Watanabe H., Domei T., Morimoto T., et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–2427.
    1. Hahn J.Y., Song Y.B., Oh J.H., et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–2437.
    1. Mehran R., Baber U., Sharma S.K., et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019 Nov 21;381(21):2032–2042.
    1. Généreux P., Giustino G., Witzenbichler B., et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036–1045.
    1. Mehran R., Rao S.V., Bhatt D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747.
    1. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–1598.
    1. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351.
    1. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
    1. Sibbing D., Aradi D., Alexopoulos D., et al. Updated expert consensus statement on platelet function and genetic testing for guiding p2y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–1537.
    1. Aradi D., Kirtane A., Bonello L., et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762–1771.
    1. Philip F., Agarwal S., Bunte M.C., et al. Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2014;7(1):49–61.
    1. Colmenarez H., Fernández C., Escaned J. Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents. EuroIntervention. 2014;10(8):942–952.
    1. Moon J.Y., Franchi F., Rollini F., et al. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis. 2018;60(4–5):478–490.
    1. Eccleston D., Horrigan M., Rafter T. Improving guideline compliance in australia with a national percutaneous coronary intervention outcomes registry. Heart Lung Circ. 2017;26(12):1303–1309.
    1. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774–782.
    1. Vaduganathan M., Harrington R.A., Stone G.W., et al. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018;13(15):e1841–e1849.
    1. Urban P., Mehran R., Colleran R., et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–261.
    1. Palmerini T., Bacchi Reggiani L., Della Riva D., et al. Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol. 2017;69(16):2011–2022.
    1. Roy P., Bonello L., Torguson R., et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol. 2008;102(12):1614–1617.
    1. Ben-Dor I., Torguson R., Scheinowitz M., et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J. 2010;159(5):871–875.
    1. Angiolillo D.J., Rollini F., Storey R.F., et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955–1975.
    1. Han Y.L. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132(2):197–210.
    1. Guo C., Li M., Lv Y.H., et al. De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Platelets. 2019:1–11.
    1. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–1517.
    1. Leonardi S., Franzone A., Piccolo R., et al. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) BMJ Open. 2019;9(3)
    1. Wang H.Y., Li Y., Xu X.M., et al. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl) 2018;131(17):2017–2024.
    1. Park T.K., Song Y.B., Ahn J., et al. Clopidogrel versus aspirin as an antiplatelet monotherapy after 12-month dual-antiplatelet therapy in the era of drug-eluting stents. Circ Cardiovasc Interv. 2016;9(1)
    1. Li J., Li Y., Qiu M., et al. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study. Catheter Cardiovasc Interv. 2020;95(Suppl. 1):579–586.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다